Orally Disintegrating Tablet (ODT)

TASCENSO ODT is the first FDA-approved MS treatment available as an easy-to-swallow, orally disintegrating tablet. It is the same proven fingolimod you are familiar with, but in a unique ODT formulation,1  accompanied by Cycle Vita, our support platform dedicated to providing support to all your eligible* patients.

With TASCENSO ODT, it’s time for convenience.

Orally Disintegrating Tablet (ODT)

TASCENSO ODT is the first FDA-approved MS treatment available as an easy-to-swallow, orally disintegrating tablet. It is the same proven fingolimod you are familiar with, but in a unique ODT formulation,1  accompanied by Cycle Vita, our support platform dedicated to providing support to all your eligible* patients.

With TASCENSO ODT, it’s time for convenience.

Tascenso Taste Free Icon

Dissolves on the tongue in seconds

Tascenso No Water Icon

Can be taken with or without water

Manufactured in the UK with each and every batch tested and verified

Not a generic 2

Not substitutable at the pharmacy level 2

Tascenso Food Icon

Can be taken with or without food

Tascenso Blister Pack Icon

No special storage conditions are required, the product should be stored at room temperature (68°F to 77°F) and protected from moisture1

dissolving tablet

Available as 0.25 mg and 0.5 mg orally disintegrating tablets

During a study of TASCENSO ODT

100%

of participants agreed TASCENSO ODT was easy to tolerate.3

89%

of participants agreed they had an overall favorable opinion of TASCENSO ODT.3

100%

of participants felt TASCENSO ODT left a pleasant taste.3

82%

of participants agreed TASCENSO ODT had no bitter after-taste.3

See TASCENSO ODT’s bioequivalenceEnroll your patients now
Pie Chart during a study of Tassenso ODT

During a study of TASCENSO ODT

100%

of participants agreed TASCENSO ODT was easy to tolerate.2

89%

of participants agreed they had an overall favorable opinion of TASCENSO ODT.2

100%

of participants felt TASCENSO ODT left a pleasant taste.2

82%

of participants agreed TASCENSO ODT had no bitter after-taste.2

See TASCENSO ODT’s bioequivalence
Enroll your patients now
Pie Chart during a study of Tassenso ODT

References

1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
2. FDA., 2023. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed June 5th 2023. Available: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
3. Data on file: REF-00068

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.